Research programme: integrin alpha-9 antagonists - Gene Techno Science/Kaken

Drug Profile

Research programme: integrin alpha-9 antagonists - Gene Techno Science/Kaken

Latest Information Update: 13 Jul 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gene Techno Science
  • Developer Gene Techno Science; Kaken Pharmaceutical
  • Class Antibodies
  • Mechanism of Action Integrin alpha9 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Autoimmune disorders; Bone disorders; Cancer

Most Recent Events

  • 09 Jul 2007 Preclinical trials in Autoimmune disorders in Japan (unspecified route)
  • 09 Jul 2007 Preclinical trials in Bone disorders in Japan (Parenteral)
  • 09 Jul 2007 Preclinical trials in Cancer in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top